Overview

Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Optimal Dose-finding Study to Evaluate the Safety and Efficacy of Botulax® in Subjects with Benign Masseteric Hypertrophy
Phase:
Phase 2
Details
Lead Sponsor:
Hugel
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A